GCP
BOLD

GSA Capital Partners’s Boundless Bio BOLD Stock Holding History

GSA Capital Partners’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Sell
72,353
-24,471
-25% -$37.7K 0.01% 1555
2026
Q1 		$107K Buy
96,824
+34,348
+55% +$40.2K 0.01% 1560
2025
Q4 		$75K Buy
+62,476
New +$77.9K 0.01% 1554

Other funds holding BOLD

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

GSA Capital Partners's BOLD Position: Q2 2026 in Review

GSA Capital Partners reduced its Boundless Bio (BOLD) stake by 25% in Q2 2026, selling an estimated $37.7K and leaving 72,353 shares worth $181K. The position accounts for 0.01% of the portfolio, ranked #1555.

GSA Capital Partners first reported a position in BOLD in Q4 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

  • GSA Capital Partners held 72,353 shares of Boundless Bio worth $181K as of Q2 2026.
  • GSA Capital Partners sold 24,471 Boundless Bio shares in Q2 2026, an estimated $37.7K.
  • Boundless Bio made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1555 holding.
  • GSA Capital Partners first reported a position in Boundless Bio in Q4 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.